文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

Wiskott-Aldrich综合征的造血干细胞移植:一项EBMT先天性错误工作组分析

Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
PubMed 文献 · Blood · 2022-01-01

该研究纳入2006至2017年间在欧洲血液与骨髓移植学会中心接受移植的197例Wiskott-Aldrich综合征患者,均接受先天性错误工作组推荐的以白消安(n=103)或曲奥舒凡(n=94)为基础的预处理方案。中位随访44.9个月后,3年总生存率为88.7%,无慢性移植物抗宿主病生存率为81.7%;预处理方案、供者类型和移植时期均未显著影响生存,但移植时年龄<5岁者总生存显著更优。

要点

  • 接受先天性错误工作组推荐方案移植的Wiskott-Aldrich综合征患者3年总生存率为88.7%,无慢性移植物抗宿主病生存率为81.7%。
  • 预处理方案(白消安 vs 曲奥舒凡)、供者类型及移植时期(2006-2013 vs 2014-2017)均未显著影响总生存和无慢性移植物抗宿主病生存。
  • 移植时年龄<5岁者总生存显著更优;曲奥舒凡组移植物失败和混合供者嵌合发生率更高,且更常接受二次手术干预。

核心结论

  • 采用先天性错误工作组当前推荐的预处理方案进行造血干细胞移植,可获得极好的生存率和较低的移植物抗宿主病发生率,与供者或干细胞来源无关,但年龄≥5岁仍是总生存的风险因素。

研究设计与样本

  • 欧洲血液与骨髓移植学会中心2006至2017年间197例接受移植的Wiskott-Aldrich综合征患者的分析,预处理为先天性错误工作组推荐的以白消安(n=103)或曲奥舒凡(n=94)为基础的方案联合氟达拉滨±塞替派。

主要发现

  • 中位移植后随访44.9个月,176例存活,3年总生存率为88.7%,无慢性移植物抗宿主病生存率(事件包括死亡、移植物失败和严重慢性移植物抗宿主病)为81.7%。
  • 总生存和无慢性移植物抗宿主病生存未受预处理方案(白消安 vs 曲奥舒凡)、供者类型(同胞相合/家族相合 vs 无关相合/无关不相合 vs 家族不相合)或移植时期(2006-2013 vs 2014-2017)显著影响。
  • 移植时年龄<5岁者总生存显著更优。
  • III至IV级急性移植物抗宿主病和广泛/中度/重度慢性移植物抗宿主病的总体累积发生率分别为6.6%和2.1%。
  • 接受曲奥舒凡为基础预处理者移植物失败和混合供者嵌合发生率更高,且更常接受二次手术(二次移植、未预处理干细胞输注、供者淋巴细胞输注或脾切除)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have improved over time with respect to overall survival, but some studies have identified older age and HSCT from alternative donors as risk factors predicting poorer outcome. We analyzed 197 patients undergoing transplant at European Society for Blood and Marrow Transplantation centers between 2006 and 2017 who received conditioning as recommended by the Inborn Errors Working Party (IEWP): either busulfan (n = 103) or treosulfan (n = 94) combined with fludarabine ± thiotepa. After a median follow-up post-HSCT of 44.9 months, 176 patients were alive, resulting in a 3-year overall survival of 88.7% and chronic graft-versus-host disease (GVHD)-free survival (events include death, graft failure, and severe chronic GVHD) of 81.7%. Overall survival and chronic GVHD-free survival were not significantly affected by conditioning regimen (busulfan- vs treosulfan-based), donor type (matched sibling donor/matched family donor vs matched unrelated donor/mismatched unrelated donor vs mismatched family donor), or period of HSCT (2006-2013 vs 2014-2017). Patients aged <5 years at HSCT had a significantly better overall survival. The overall cumulative incidences of grade III to IV acute GVHD and extensive/moderate/severe chronic GVHD were 6.6% and 2.1%, respectively. Patients receiving treosulfan-based conditioning had a higher incidence of graft failure and mixed donor chimerism and more frequently underwent secondary procedures (second HSCT, unconditioned stem cell boost, donor lymphocyte infusion, or splenectomy). In summary, HSCT for WAS with conditioning regimens currently recommended by IEWP results in excellent survival and low rates of GVHD, regardless of donor or stem cell source, but age ≥5 years remains a risk factor for overall survival.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Albert MH, Slatter MA, Gennery AR, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood. 2022. PMID: 35100336. doi:10.1182/blood.2021014687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。